EMA Withdrawn: Ivozall (clofarabine) — ORPHELIA Pharma

View source ↗

Summary

EMA has withdrawn Ivozall (clofarabine) from the market for the therapeutic area of precursor cell lymphoblastic leukemia-lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Ivozall (clofarabine)

Snippet

Status: Withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: ORPHELIA Pharma. Decision date: 06/03/2023